Citations (5)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Prateesh Varughese, Robert Smith, Mei Xue, Natalie Dorrow, Cosmina Hogea, Eric.M Maiese & Trudy Buckingham. (2023) Real-world treatment patterns and outcomes of triple-class treated patients with multiple myeloma in the United States. Expert Review of Hematology 16:1, pages 65-74.
Read now
Read now
Karla S. Romero-Aguilar, Ivonne M. Arciniega-Martínez, Eunice D. Farfán-García, Rafael Campos-Rodríguez, Aldo A. Reséndiz-Albor & Marvin A. Soriano-Ursúa. (2019) Effects of boron-containing compounds on immune responses: review and patenting trends. Expert Opinion on Therapeutic Patents 29:5, pages 339-351.
Read now
Read now
Guldane Cengiz Seval & Meral Beksac. (2018) The safety of bortezomib for the treatment of multiple myeloma. Expert Opinion on Drug Safety 17:9, pages 953-962.
Read now
Read now
Antonio Palumbo, Massimo Offidani, Francesca Patriarca, Maria Teresa Petrucci & Michele Cavo. (2015) Bendamustine for the treatment of multiple myeloma in first-line and relapsed–refractory settings: a review of clinical trial data. Leukemia & Lymphoma 56:3, pages 559-567.
Read now
Read now
Morie A. Gertz. (2008) New targets and treatments in multiple myeloma: Src family kinases as central regulators of disease progression. Leukemia & Lymphoma 49:12, pages 2240-2245.
Read now
Read now